Dr Alex LUGOVSKOY

Dr Alex LUGOVSKOY (PhD in Biophysics) – Author of the Patent for MM141

Dr Alex Lugovskoy has joined Atlas Venture as Entrepreneur-in-Residence in January 2022. He has co-founded and leads Diagonal Therapeutics, a company that aims to capitalize on untapped opportunities for antibody receptor agonists as drugs. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

Executive Team

 

Chief Executive Officer
 

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse.

Jean-Pierre

ARMAND

Chief Executive Officer

Chief Scientific Officer
 

MD PhD, is medical oncologist by training and is currently working at Institut Gustave Roussy as head of the Hematology department and head of the early drug development tumor board.

Vincent

RIBRAG

Chief Scientific Officer

Deputy Chief Scientific Officer
 

Obtained a PhD from Paris VI University in 2005 focused on metabolic disorders, and an EMBO long-term postdoctoral fellowship at ETH-Zürich for a project of pancreatic cancer biomarker.

Alexandre

BOBARD

Deputy Chief Scientific Officer

Translational Science
 

Obtained a PhD from the Paris VII University in 2003. His research studies at the Pasteur Institute were dedicated to the analysis of the immunogenetic and viral factors controlling the evolution of papillomavirus-associated tumors

Jerome

SALMON

Translational Science

COO/CFO
 

Jean-Paul Alves, BSc in Economy, Graduated from EM Lyon and Post Graduated in Managerial Accounting, Chartered Accounting and Tax, joined Pegascy in 2020 as Chief Financial Officer.

Jean-Paul

ALVES

COO/CFO


Tumor Board

 

Oncopediatrician
 

MD, PhD, is pediatric oncologist heading the Pediatric Early Drug Development Program of Institut Gustave Roussy.

Birgit

GEOERGER

Oncopediatrician

Oncopediatrician
 

Olivier Delattre : MD, PhD was trained in pediatric oncology and genetics. His research area mainly investigates the genetic and biology of pediatric cancers.

Olivier

DELATTRE

Oncopediatrician

Oncopediatrician
 

Pierre Busson is a Senior Research Scientist at the CNRS and Gustave Roussy (DR1 CNRS, UMR 9018, Villejuif, France). He obtained his M.D. in 1983 and his Ph.D. in Virology in 1990 from Paris University.

Pierre

BUSSON

Nasopharynx cancer

Oncopediatrician
 

Alexandra Leary is a Medical Oncologist and Translational Researcher specializing in gynaecological tumors at Gustave Roussy

Alexandra

LEARY

Gynaecology


Scientific Advisory Board

 

Head of Pegascy’s
 

Christophe Massard, Head of Pegascy’s SAB, ex-Head of In-patient Unit at Drug Development Department (DITEP), Gustave Roussy

Christophe

MASSARD

Associate Director of Experim
 

Patricia LoRusso, Associate Director of Experim. Therapeutics at Yale Cancer Center (US) More than 25 years of expertise in medical oncology

patricia

LORUSSO

 

ESMO President
 

Josep Tabernero, ESMO President, Head of the Medical Oncology Department at the Vall d’Hebron Hospital Campus (Barcelone ,Spain)

josep

TABERNERO

 

Medical Oncologist at the Un. of Texas
 

Thimothy Yap, Medical Oncologist at the Un. of Texas MD Anderson Cancer Center (US)

Thimothy

YAP

 

Deputy Director of the Drug Development
 

Udai Banerji, Deputy Director of the Drug Development Unit at The ICR (London, UK)

Udai

BANERJI

 

V-President Group Head & Clinical Oncology Dev.
 

Jean-Pierre Bizzari, ex-Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, Asia)

Jean-Pierre

BIZZARI

 

CEO of the Centre Leon Berard
 

Jean-Yves Blay, CEO of the Centre Leon Berard (Lyon ,France) and President of UNICANCER Professor in Medical Oncology

Jean-Yves

BLAY

 

Director,Translational Cancer Medicine
 

Susan Bates, Director, Translational Cancer Medicine, Division of Hematology/Oncology of the Herbert Irving Comprehensive Cancer Center

Susan

BATES

 

Director,Translational Cancer Medicine
 

Dr. Melero started out in biomedical research as a resident of immunology at the prestigious department of this specialty in Hospital Universitario de la Princesa (Madrid).

Ignacio

MELERO

 

Senior Advisor
 

Professor Emeritus, Medical Oncology, University of Nantes, France; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, France Jean-Yves Douillard trained at the Medical School...

Jean-Yves

DOUILLARD


Experts

Regulatory
 

Professor Jean-Hugues Trouvin graduated in Pharmacy and received his State Doctorate in Pharmacology from the University of Paris.

Jean-Hugues

TROUVIN

Regulatory

Manufacturing
 

Aurelio ZERIAL is doctor in Biology (University of Trieste, Italy) and PhD in Biochemistry (1978 -Wesleyan University, USA).

Aurelio

ZERIAL

Manufacturing

Quality
 

After studying pharmacy at Grenoble and Lyon Universities, I am now living in Normandy with my family.

Marion

ORSET

Quality

IP
 

Florence Allouche: Founder and President of MYRPHARM ADVISORS, a consulting firm helping translational academic research

Florence

ALLOUCH

IP

Istiratumab CMC
 

Antoine (Tony) Awad joined Synlogic in December 2018 as Head of Technical Operations and is responsible for process sciences and manufacturing functions for the Company. 

Antoine

AWAD

Istiratumab CMC

Istiratumab Inventor
 

Dr Alex Lugovskoy has joined Atlas Venture as Entrepreneur-in-Residence in January 2022.

Alexey

LUGOVSKOY

Istiratumab Inventor